[go: up one dir, main page]

WO2003038032A3 - Means for inhibition of the synthesis of viral proteins - Google Patents

Means for inhibition of the synthesis of viral proteins Download PDF

Info

Publication number
WO2003038032A3
WO2003038032A3 PCT/DE2002/004052 DE0204052W WO03038032A3 WO 2003038032 A3 WO2003038032 A3 WO 2003038032A3 DE 0204052 W DE0204052 W DE 0204052W WO 03038032 A3 WO03038032 A3 WO 03038032A3
Authority
WO
WIPO (PCT)
Prior art keywords
vpr
hiv
immune deficiency
inhibitors
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2002/004052
Other languages
German (de)
French (fr)
Other versions
WO2003038032A2 (en
WO2003038032A8 (en
Inventor
Hans Will
Uwe Tessmer
Karsten Bruns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE20220744U priority Critical patent/DE20220744U1/en
Priority to EP02782752A priority patent/EP1439853A2/en
Priority to AU2002347102A priority patent/AU2002347102A1/en
Publication of WO2003038032A2 publication Critical patent/WO2003038032A2/en
Publication of WO2003038032A8 publication Critical patent/WO2003038032A8/en
Publication of WO2003038032A3 publication Critical patent/WO2003038032A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to means for inhibition of primate lentiviruses, in particular the use of PPIase inhibitors as means for inhibiting human immune deficiency viruses type 1 and 2 (HIV-1 and HIV-2) and simian immune deficiency viruses (SIV). It can be shown using viral protein R (Vpr), that inhibitors of cellular peptidyl-prolyl cis/trans isomerases (PPIases) inhibit the expression, folding protein stability and the biological efficacy of Vpr. The anti-viral effect of PPIase inhibitors, in particular, cyclosporin A, is based on a specific interaction of PPIases, in particular of cyclophilin A, with prolines on the N-terminus of Vpr. Applications are in anti-retroviral therapy and prevention of infections with lentiviruses which cause immune deficiency in humans and animals, in particular of AIDS or HIV-induced pathological conditions, also in combination with other anti-retroviral medicaments.
PCT/DE2002/004052 2001-10-25 2002-10-25 Means for inhibition of the synthesis of viral proteins Ceased WO2003038032A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE20220744U DE20220744U1 (en) 2001-10-25 2002-10-25 Lentivirus inhibitor
EP02782752A EP1439853A2 (en) 2001-10-25 2002-10-25 Means for inhibition of lentiviruses
AU2002347102A AU2002347102A1 (en) 2001-10-25 2002-10-25 Means for inhibition of the synthesis of viral proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10153902.9 2001-10-25
DE10153902 2001-10-25

Publications (3)

Publication Number Publication Date
WO2003038032A2 WO2003038032A2 (en) 2003-05-08
WO2003038032A8 WO2003038032A8 (en) 2003-08-14
WO2003038032A3 true WO2003038032A3 (en) 2003-10-30

Family

ID=7704423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/004052 Ceased WO2003038032A2 (en) 2001-10-25 2002-10-25 Means for inhibition of the synthesis of viral proteins

Country Status (4)

Country Link
EP (1) EP1439853A2 (en)
AU (1) AU2002347102A1 (en)
DE (1) DE20220744U1 (en)
WO (1) WO2003038032A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361944A1 (en) * 2003-12-31 2005-07-28 Viromics Gmbh Agent for inhibiting virus replication by regulating protein folding

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0484281A2 (en) * 1990-11-02 1992-05-06 Sandoz Ltd. Cyclosporins
WO1997033604A1 (en) * 1996-03-12 1997-09-18 Picower Institute For Medical Research Treatment of hiv-infection by interfering with host cell cyclophilin receptor activity
WO2003038056A2 (en) * 2001-11-02 2003-05-08 The Regents Of The University Of California Methods for inhibiting lentivirus replication

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0484281A2 (en) * 1990-11-02 1992-05-06 Sandoz Ltd. Cyclosporins
WO1997033604A1 (en) * 1996-03-12 1997-09-18 Picower Institute For Medical Research Treatment of hiv-infection by interfering with host cell cyclophilin receptor activity
WO2003038056A2 (en) * 2001-11-02 2003-05-08 The Regents Of The University Of California Methods for inhibiting lentivirus replication

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRIGGS C J ET AL: "Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV -1.", ARCHIVES OF VIROLOGY, (1999) 144 (11) 2151-60., XP000993073 *
HUSS, RALF: "Inhibition of cyclophilin function in HIV -I infection by cyclosporin A", IMMUNOLOGY TODAY (1996), 17(6), 259-260, XP004034608 *
MINDER D ET AL: "Immunophilins and HIV -1 infection.", ARCHIVES OF VIROLOGY, (2002 AUG) 147 (8) 1531-42., XP002251068 *
MLYNAR E ET AL: "The non-immunosuppressive cyclosporin A analogue SDZ NIM 811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficiency virus type 1-infected primary and growth-arrested T cells.", THE JOURNAL OF GENERAL VIROLOGY. ENGLAND APR 1997, vol. 78 ( Pt 4), April 1997 (1997-04-01), pages 825 - 835, XP002251070, ISSN: 0022-1317 *
STEINKASSERER A ET AL: "Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 ( HIV -1): interference with early and late events in HIV -1 replication.", JOURNAL OF VIROLOGY, (1995 FEB) 69 (2) 814-24., XP002251069 *
STREBLOW D N ET AL: "Cyclophilin a modulates processing of human immunodeficiency virus type 1 p55Gag: mechanism for antiviral effects of cyclosporin A.", VIROLOGY, (1998 JUN 5) 245 (2) 197-202., XP002251067 *

Also Published As

Publication number Publication date
EP1439853A2 (en) 2004-07-28
WO2003038032A2 (en) 2003-05-08
DE20220744U1 (en) 2004-05-13
WO2003038032A8 (en) 2003-08-14
AU2002347102A1 (en) 2003-05-12

Similar Documents

Publication Publication Date Title
ATE264914T1 (en) ANTIVIRAL PROTEINS, DNA CODING THEREOF, AND USE THEREOF
EA200200724A1 (en) VACCINE FOR PREVENTION OR THERAPEUTIC IMMUNIZATION AGAINST THE VIRUS OF HUMAN IMMUNODEFICIENCY (HIV)
CA2217737A1 (en) Thf-containing sulfonamide inhibitors of aspartyl protease
AP1717A (en) Sulfonamide inhibitors of aspartyl protease.
WO2004096818A3 (en) Method and compositions for identifying anti-hiv therapeutic compounds
TW200510425A (en) Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
MY115797A (en) Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
BR9607625A (en) Retroviral protease inhibitors hydroxyethylamino hydroxyethylamino amino acid heterocyclocarbonyl
NO20020571L (en) Peptides that block infectivity and methods for their use
EP1637518A3 (en) Inhibitors of aspartyl protease
WO2004029201A3 (en) Peptide derivative fusion inhibitors of hiv infection
WO2003038032A3 (en) Means for inhibition of the synthesis of viral proteins
ATE374208T1 (en) PHARMACOLOGICALLY ACTIVE ANTIVIRAL PEPTIDES AND METHODS OF THEIR USE
CA2195125A1 (en) Difluorostatone antiviral agents
GR3024226T3 (en) Antiviral naphthoquinone compounds, compositions and uses thereof.
WO2022125378A8 (en) Combination therapy
WO2007002172A3 (en) Hiv-1 protease inhibitors
WO2002064154A3 (en) Methods and compositions for inhibiting hiv-coreceptor interactions
MXPA04004061A (en) Antiretroviral pyridine and quinoline derivatives.
UA41338C2 (en) METHOD OF INHIBITION OF RETROVIRUS INFECTION CAUSED BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), METHOD OF IMMUNIDUF IMMUNODE VIRUS INHIBITION
WO2002034909A3 (en) Engineered chimera of hiv protein fragments and uses thereof
DK0545991T3 (en) Peptides that block human immunodeficiency virus infections, and methods for their use
AP2003002852A0 (en) Natural antibodies active against HIV virus
WO2003104262A3 (en) GP41 PEPTIDES AND METHODS USING SUCH PEPTIDES TO INHIBIT HIV FUSION WITH TARGET CELLS
GB2382529A (en) Immunomodulator for the management of human immunodficiency virus (hiv) disease/infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 19/2003 UNDER (72) DELETE ""SCHUBERT, ULRICH; JENAISCHE STRASSE 51, 07407 UHLSTAEDT (DE).""

WWE Wipo information: entry into national phase

Ref document number: 2002782752

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002782752

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP